TrialJAMA network open2026

Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.

Sancy A Leachman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.